Clinical trial
Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose…
NCT00040586 · BZL Biologics, Industry · Completed
Key facts
| NCT number | NCT00040586 |
|---|---|
| Title | Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2 |
| Official title | Phase II Trial of Monoclonal Antibody J591 in Combination With Low-Dose Interleukin-2 in Patients With Recurrent Prostate Cancer |
| Lead sponsor | BZL Biologics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Monoclonal Antibody J591, Recombinant Interleukin-2 |
| First posted | Jul 2, 2002 |
| Last update posted | Jan 22, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: